Aktiesnakken — April 2011
-
nej leoloo?
-
i chatten eller gruppen eller debatten?
-
det ser jo rigtigt rigtigt spændende ud
-
og emerging role!
-
the hematology community is seeing that the novel CD20 directed antibody, Ofa
-
can be highly effective in high risk CLL patient populations with acceptable toxicity
-
ja Pete
-
vi har vel heller ikke før set data med OFC?
-
OR rates were 77% (CR 32%) and 73% (CR 50%)
-
hvornår er den fra 2011: 5?
-
det er rigtig spændende med OFC
-
fordi det i høj grad er dette kombinationsstudie som har cementeret rituxians markedsposition på det sidste
-
men hvordan kan vi tolke det anderledes end at Arzerra er på vej frem
-
og mayo er den førende klinik
-
jeg vil tro de tager omrking 4-6 år herfra
-
mindst hvis alt går godt. og fase 1 tager 10+ år
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind